RxDoctor Payments Data
★ My doctorsLook up a doctor →

Steven Conrad, MD

Critical Care Medicine · Shreveport, LANPI 1124048004

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $9,761 of the $14,529 with a category attached, or 67.2%. Biomerieux Inc accounts for 68.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $10,140 and has fallen 91.7% since, to $842 in 2025. Among critical care medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,529in general payments, 2019–2025

Across 73 payments — averaging $199.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomerieux Inc$10K
  • Livanova USA, Inc.$800
  • Abiomed$751
  • AstraZeneca$467
  • Actelion Pharmaceuticals US, Inc.$359
  • Nxstage Medical, Inc.$326
  • plus $2K from 21 others
$104,087in research payments, 2019–2025

Across 18 payments — averaging $5782.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Grifols Therapeutics LLC$82K
  • Immedica Pharma US, Inc.$16K
  • Biomerieux Inc$7K

What the payments were for

  • Speaking & faculty fees$8006%
  • Travel & lodging$9,76167%
  • Food & beverage$3,96827%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biomerieux Inc2$9,888
Livanova USA, Inc.1$800
Abiomed10$751
AstraZeneca9$467
Actelion Pharmaceuticals US, Inc.9$359
Nxstage Medical, Inc.5$326
Paratek Pharmaceuticals, Inc.2$250
Baxter Healthcare5$225
La Jolla Pharmaceutical Company3$171
Chiesi USA, Inc.1$147
AbbVie2$140
Michigan Critical Care Consultants, Inc.1$126
Sanofi1$125
GSK1$125
Gilead1$125
Getinge USA Sales, LLC2$109
Boehringer Ingelheim5$106
Mallinckrodt Enterprises LLC1$95
Takeda Pharmaceuticals U.S.A., Inc.2$30
Vapotherm Inc1$27
Insmed, Inc.2$26
Genentech USA, Inc.2$26
Resmed Corp1$20
Regeneron Healthcare Solutions, Inc.1$20
Mallinckrodt Hospital Products Inc.1$16
Merck1$13
Pfizer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,529 in reported general payments places this provider in the 90th percentile of 72 critical care medicine providers in Louisiana.

See all critical care medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024
$48,726
Medicare patients
115
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Shreveport

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →